WEST COLUMBIA, S. C. – NBC News recently visited Nephron Pharmaceuticals Corporation to report on the company’s educator program that employs more than 650 local teachers, each of whom assist Nephron’s more than 1,000 employees, giving these educators the opportunity to earn secondary income.
“We are grateful for our teachers, we are proud of how hard they work with our children and at Nephron, and we hope other companies across S.C. will join us in supporting them in and out of the classroom,” said Nephron Pharmaceuticals Company CEO Lou Kennedy.
Nephron announced the educator program earlier this year. The mission is to provide secondary income to educators as they help Nephron fill and complete orders.
Educators are focused specifically on the Nephron 503B outsourcing division which services U.S. hospitals and surgery centers with drug shortage needs. Nephron is able to complete orders faster with the support of these teachers and administrators.
According to NBC News, “Nephron Pharmaceuticals does not want to lure teachers away from the profession. The educator program was created by the drug manufacturer’s female CEO and president, Lou Kennedy, whose mother was a teacher; it caps teachers’ hours at 40 a month. Kennedy said her goal is to show ‘how much we should respect teachers and how much they mean to us’ and show legislators that teachers need more money and support.”
Nephron Pharmaceuticals Corporation develops and manufactures safe, affordable generic inhalation solution and suspension products specializing in Blow-Fill-Seal technology. In addition, the company operates an industry-leading 503B Outsourcing Facility division which produces pre-filled sterile syringes and IV bags for hospitals across America, in an effort to alleviate their drug shortage needs. In accordance with the DQSA draft guidance, the company follows cGMP, GDP and all quality expectations. The company has been licensed by the Food and Drug Administration. Nephron received a 2017 ISPE/FOYA innovation award for the high level of automation present throughout the facility. For more information, please visit www.nephronpharm.com.